NCT05165719 is a clinical trial of Corona-T-test in SARS-CoV-2 Infection, sponsored by National Research Center for Hematology, Russia.

Who is sponsoring NCT05165719?

NCT05165719 is sponsored by National Research Center for Hematology, Russia.

What drugs are being tested in NCT05165719?

Interventions in NCT05165719: Corona-T-test.

What condition does NCT05165719 study?

NCT05165719 studies SARS-CoV-2 Infection, SARS-CoV-2 Vaccination.

Is NCT05165719 still recruiting?

NCT05165719 is currently completed. Last updated 21 December 2021.

Last reviewed 2021-12-21 · How we verify

NCT05165719

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Validation of 'Corona-T-test' for Assessment of SARS-COV-2-specific T-cell Response After COVID-19 or Vaccination

Completed Last updated 21 December 2021

What this trial tests

trial testing Corona-T-test in SARS-CoV-2 Infection in 220 participants. Completed in 20 November 2021.

Timeline

7 July 2021

Primary endpoint
21 September 2021

20 November 2021

Quick facts

Lead sponsor	National Research Center for Hematology, Russia
Status	Completed
Study type	OBSERVATIONAL
Enrollment	220
Start date	7 July 2021
Primary completion	21 September 2021
Estimated completion	20 November 2021
Sites	1 location across Russia

Drugs / interventions tested

Corona-T-test

Conditions studied

SARS-CoV-2 Infection — all drugs for SARS-CoV-2 Infection →
SARS-CoV-2 Vaccination — all drugs for SARS-CoV-2 Vaccination →

Sponsor

National Research Center for Hematology, Russia — full company profile →

Who can join

18 and older, any sex, with SARS-CoV-2 Infection or SARS-CoV-2 Vaccination. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Accuracy validation of the designed and manufactured ELISpot-based in vitro diagnostic 'Corona-T-test' for detection of SARS-CoV-2-specific T cells.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Immunogenic epitope panel for accurate detection of non-cross-reactive T cell response to SARS-CoV-2.
Titov A, Shaykhutdinova R, Shcherbakova OV, Serdyuk YV, et al · · 2022 · cited 20× · PMID 35389886 · DOI 10.1172/jci.insight.157699

Verify or expand the search:

Other recruiting trials for SARS-CoV-2 Infection

Currently open trials in the same condition.

NCT07079670 — Safety and Immunogenicity of NVX-CoV2705 · Phase 3 · active not recruiting
NCT05697068 — Intervention to Prevent Household and Community Spread of COVID-19 Among Latinos · NA · active not recruiting
NCT05172011 — Understanding the Long-term Impact of COVID on Children and Families · active not recruiting
NCT05141058 — T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients · Phase 1 · recruiting
NCT05046470 — SARS-CoV-2 Transmission in Belgian Primary Schools of the Federation Wallonia - Brussels: An Epidemiological Pilot Study · active not recruiting

Other National Research Center for Hematology, Russia trials

Trials by the same sponsor.

NCT06721598 — An Extension Study to Evaluate the Safety and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell Lymphoproli · not yet recruiting
NCT06705530 — A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphop · Phase 1, PHASE2 · completed
NCT06237192 — MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients · NA · recruiting
NCT06188676 — Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunother · Phase 3 · recruiting
NCT05158608 — Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis · Phase 3 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05165719 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Research Center for Hematology, Russia
Last refreshed: 21 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05165719.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing